OX40 ligand levels and high-sensitivity C-reactive protein levels in blood from local coronary plaque and the femoral artery in patients with acute coronary syndrome or stable angina

Journal of International Medical Research

Volumn 39, Issue 4, 2011, Pages 1275-1283

  Shi, J Z ^a   Wang, L Y ^a   Zhu, Y ^a   Zhao, C Y ^a   Liu, W ^a   Jiang, S L ^a   You, H W ^a   Wang, Y ^a   Xu, F Y ^a   Tang, Y S ^a   Cui, L Q ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Coronary plaque; Fibrinogen; High sensitivity C reactive protein; OX40 ligand

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OX40 LIGAND;

ACCURACY; ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DISEASE MARKER; FEMALE; FEMORAL ARTERY; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

EID: 80052211343     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900415     Document Type: Article

References (26)

1. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
2. Hansson GK, Libby P: The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-519.
3. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
4. Katritsis D, Korovesis S, Giazitzoglou E, et al: CReactive protein concentrations and angiographic characteristics of coronary lesions. Clin Chem 2001; 47: 882-886.
5. Saleh N, Tornvall P: Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis 2007; 195: 374-378.
6. Muhlestein JB, Horne BD, Carlquist JF, et al: Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000; 102: 1917-1923.
7. Figaro MK, Kritchevsky SB, Resnick HE, et al: Diabetes, inflammation, and functional decline in older adults: findings from the Health, Aging and Body Composition (ABC) study. Diabetes Care 2006; 29: 2039-2045.
8. Wang X, Ria M, Kelmenson PM, et al: Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005; 37: 365-372.
9. Higgins LM, McDonald SA, Whittle N, et al: Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand- IgG fusion protein. J Immunol 1999; 162: 486-493.
10. Carboni S, Aboul-Enein F, Waltzinger C, et al: CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol 2003; 145: 1-11.
11. Nohara C, Akiba H, Nakajima A, et al: Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol 2001; 166: 2108-2115.
12. van Wanrooij EJ, van Puijvelde GH, de Vos P, et al: Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 204-210.
13. Liu DM, Yan JC, Wang CP, et al: The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta 2008; 397: 22-26.
14. Ledue TB, Weiner DL, Sipe JD, et al: Analytical evaluation of particle-enhanced immuno - nephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998; 35: 745-753.
15. National Committee for Clinical Laboratory Standards (NCCLS): Procedure for the Determination of Fibrinogen in Plasma, Approved Guideline H30-A. NCCLS: Wayne, PA, 1999: p 99.
16. Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
17. Paterson DJ, Jefferies WA, Green JR, et al: Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol 1987; 24: 1281-1290.
18. + T cells with homology to tumor necrosis factor. J Exp Med 1994; 180: 757-762.
19. Sugamura K, Ishii N, Weinberg AD: Therapeutic targeting of the effector T-cell costimulatory molecule OX40. Nat Rev Immunol 2004; 4: 420-431.
20. Norja S, Nuutila L, Karhunen PJ, et al: Creactive protein in vulnerable coronary plaques. J Clin Pathol 2007; 60: 545-548.
21. Danenberg HD, Szalai AJ, Swaminathan RV, et al: Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108: 512-515.
22. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
23. Torzewski M, Rist C, Mortensen RF, et al: Creactive protein in the arterial intima: role of Creactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-2099.
24. Haverkate F, Thompson SG, Pyke SD, et al: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-466.
25. Green D, Foiles N, Chan C, et al: Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis 2009; 202: 623-631.
26. Viles-Gonzalez JF, Fuster V, Badimon JJ: Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004; 25: 1197-1207.